Moderna (NASDAQ: MRNA) shares extended their recent surge on Thursday, climbing roughly 8% as investors digested the company's landmark Phase 3 data for its personalized mRNA cancer vaccine and a flurry of analyst actions. The stock has now more than doubled over the past month, reflecting a sharp shift in sentiment toward the biotech's pipeline beyond COVID-19.
Phase 3 win for intismeran autogene
The rally stems from the INTerpath-001 trial, a Phase 3 study conducted with Merck (NYSE: MRK) that evaluated intismeran autogene (formerly mRNA-4157) in combination with Keytruda versus Keytruda alone. The trial enrolled over 1,100 patients with high-risk melanoma and met its primary endpoint of recurrence-free survival, with the combination significantly reducing the risk of melanoma recurrence or death.
This marks the first positive Phase 3 readout for a personalized mRNA cancer vaccine, a milestone that could reshape the treatment landscape for solid tumors. The vaccine is custom-built for each patient based on mutations identified in their tumor tissue, and no new safety signals were observed.
Moderna and Merck are advancing a broader clinical program spanning nine trials across melanoma, lung, bladder, and kidney cancers, suggesting the potential opportunity extends well beyond the initial indication.
Analyst reactions split
Wall Street has responded with a mix of upgrades and cautious notes. Argus Research upgraded Moderna to Buy with a $180 price target on August 28, citing the vaccine's promise and the recent FDA approval of the company's updated COVID-19 shots. Wolfe Research lifted its rating to Peer Perform on August 25.
However, Rothschild & Co cut its rating to Sell on September 3, though it raised its price target to $81. Evercore ISI maintains a Hold rating. The consensus stands at Hold with an average price target of $91, implying limited upside from current levels—a sign that much of the good news may already be priced in.
Momentum leader in healthcare
Moderna's year-to-date gain of nearly 394% places it among the top-performing large-cap healthcare stocks, according to Seeking Alpha's Quant Momentum Grade, which awards it an A+. The dramatic move underscores a narrative shift as investors look beyond the company's COVID-19 franchise to its oncology pipeline.
Still, the wide divergence in analyst targets highlights the uncertainty around commercial adoption, pricing, and competition. While the cancer vaccine data is encouraging, the path to regulatory approval and market uptake remains lengthy and fraught with challenges.
For context, other recent market moves—such as XRP's leverage reset and CoreWeave's gains on Nvidia's Rubin cluster—show how momentum can shift quickly across sectors. Moderna's rally, however, is driven by fundamental clinical progress rather than speculative trading.
Investors will now watch for additional data readouts from the broader cancer program, as well as regulatory interactions that could determine the vaccine's commercial future. The company's ability to translate this clinical win into sustained revenue growth will be key to justifying the current valuation.
This article is for informational purposes only and does not constitute financial advice.
